A Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects With Advanced Solid Tumors and Subsequent Dose Expansion Cohorts
Number: NCT02266745
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Phosplatin Therapeutics
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Gallium-68 Citrate PET Used in Prostate Cancer
Number: NCT02391025
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Early Phase 1
Sponsor(s): Rahul Aggarwal|United States Department of Defense|University of California, San Francisco
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Study of TGF-β Receptor Inhibitor Galunisertib (LY2157299) and Enzalutamide in Metastatic Castration-resistant Prostate Cancer
Number: NCT02452008
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Eli Lilly and Company
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can
Number: NCT02484404
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Docetaxel With or Without Ascorbic Acid in Treating Patients With Metastatic Prostate Cancer
Number: NCT02516670
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Enzalutamide With and Without Ribociclib for Metastatic, Castrate-Resistant, Chemotherapy-Naive Prostate Cancer That Retains RB Expression
Number: NCT02555189
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Sidney Kimmel Cancer Center at Thomas Jefferson University|Novartis|Prostate Cancer Clinical Trials Consortium|Thomas Jefferson University
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Study of TAS3681 in Metastatic Castration Resistant Prostate Cancer
Number: NCT02566772
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Taiho Oncology, Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer
Number: NCT02635672
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Vincerx Pharma, Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications
Number: NCT02649790
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Karyopharm Therapeutics Inc
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Safety and Activity Study of PSCA-Targeted CAR-T Cells (BPX-601) in Subjects With Selected Advanced Solid Tumors
Number: NCT02744287
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Bellicum Pharmaceuticals
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer
Number: NCT02769962
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)
Sponsor Trial Information
Trial Location(s) and Contact(s) |
18F-FMAU PET/CT in Diagnosing and Characterizing Prostate Cancer
Number: NCT02809690
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): University of Southern California|National Cancer Institute (NCI)|National Institute for Biomedical Imaging and Bioengineering (NIBIB)
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Preliminary Evaluation of Uptake in Bone Metastases and Biodistribution of [68Ga]P15-041
Number: NCT02826382
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Early Phase 1
Sponsor(s): Five Eleven Pharma, Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)
Number: NCT02861573
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Merck Sharp & Dohme Corp.
Sponsor Trial Information
Trial Location(s) and Contact(s) |
PROSTVAC in Combination With Nivolumab in Men With Prostate Cancer
Number: NCT02933255
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Enzalutamide and Indomethacin in Treating Patients With Recurrent or Metastatic Hormone-Resistant Prostate Cancer
Number: NCT02935205
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Mamta Parikh|National Cancer Institute (NCI)|University of California, Davis
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects
Number: NCT03012321
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Northwestern University|AstraZeneca|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer
Number: NCT03016741
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 4
Sponsor(s): Northwestern University
Sponsor Trial Information
Trial Location(s) and Contact(s) |
INJECT: A Pilot Study of Intra-tumoral Injections in Metastatic Urological Cancers
Number: NCT03071328
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Early Phase 1
Sponsor(s): Duke University
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Preliminary Evaluation of Uptake of [68Ga]P16-093 in Metastatic Prostate and Renal Cancer
Number: NCT03073395
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Five Eleven Pharma, Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s) |
CART-PSMA-TGFβRDN Cells for Castrate-Resistant Prostate Cancer
Number: NCT03089203
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): University of Pennsylvania
Sponsor Trial Information
Trial Location(s) and Contact(s) |
A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Minnelideâ„¢ Capsules Given Alone or in Combination With Protein-Bound Paclitaxel in Patients With Advanced Solid Tumors
Number: NCT03129139
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Minneamrita Therapeutics LLC|Translational Drug Development
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
Number: NCT03170960
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Exelixis
Sponsor Trial Information
Trial Location(s) and Contact(s) |
A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma
Number: NCT03207867
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Novartis Pharmaceuticals|Novartis
Sponsor Trial Information
Trial Location(s) and Contact(s) |
PSMA-based 18F-DCFPyL PET/CT and PET/MRI Pilot Studies in Prostate Cancer
Number: NCT03232164
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Early Phase 1
Sponsor(s): University of Wisconsin, Madison
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Cisplatin in Castration Resistant Prostate Cancer
Number: NCT03275857
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Early Phase 1
Sponsor(s): University of Rochester|Roswell Park Cancer Institute
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Testing the Safety of Different Doses of Olaparib Given Radium-223 for Men With Advanced Prostate Cancer With Bone Metastasis
Number: NCT03317392
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Enzalutamide With or Without Radium Ra 223 Dichloride in Patients With Metastatic, Castration-Resistant Prostate Cancer
Number: NCT03344211
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): University of Southern California|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Radium Ra 223 Dichloride, Hormone Therapy and Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Prostate Cancer
Number: NCT03361735
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): City of Hope Medical Center
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Highly Conformal, Hypofractionated, Focally Dose Escalated Post-Prostatectomy Radiotherapy
Number: NCT03388619
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)
Sponsor Trial Information
Trial Location(s) and Contact(s) |
PET/MRI for the Staging of Newly Diagnosed Prostate Cancer
Number: NCT03392181
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Early Phase 1
Sponsor(s): Northwestern University|Progenics Pharmaceuticals, Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Pembrolizumab and HER2Bi-Armed Activated T Cells in Treating Patients With Metastatic Castration Resistant Prostate Cancer
Number: NCT03406858
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Barbara Ann Karmanos Cancer Institute|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Onvansertib in Combination With Abiraterone and Prednisone in Adult Patients With Metastatic Castration-Resistant Prostate Cancer
Number: NCT03414034
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Cardiff Oncology
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Safety and Pharmacokinetics of ODM-208 in Patients With Metastatic Castration-resistant Prostate Cancer
Number: NCT03436485
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Orion Corporation, Orion Pharma
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Study to Evaluate CORT125281 in Combination With Enzalutamide in Patients With mCRPC
Number: NCT03437941
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Corcept Therapeutics
Sponsor Trial Information
Trial Location(s) and Contact(s) |
CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers
Number: NCT03454451
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Corvus Pharmaceuticals, Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Therapeutic Effect of Cytoreductive Radical Prostatectomy in Men With Newly Diagnosed Metastatic Prostate Cancer
Number: NCT03456843
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Yale University|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s) |
PF-06821497 Treatment Of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
Number: NCT03460977
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Pfizer
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, N-803 and Epacadostat (QuEST1)
Number: NCT03493945
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Assessing Induction of Double Strand Breaks With Androgen Receptor Partial Agonist in Patients on Androgen Suppression
Number: NCT03507608
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Early Phase 1
Sponsor(s): Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Sponsor Trial Information
Trial Location(s) and Contact(s) |
A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors
Number: NCT03517488
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Xencor, Inc.|ICON plc
Sponsor Trial Information
Trial Location(s) and Contact(s) |
A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies.
Number: NCT03549000
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Novartis Pharmaceuticals|Novartis
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Oral TrkA Inhibitor VMD-928 for Treatment of Advanced Adult Solid Tumors or Lymphoma
Number: NCT03556228
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): VM Oncology, LLC
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Study to Evaluate CCS1477 in Advanced Tumours
Number: NCT03568656
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): CellCentric Ltd.
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Evaluation of Safety and Efficacy of KPG-121 Plus Enzalutamide, Abiraterone or Apalutamide in CRPC Patients
Number: NCT03569280
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Kangpu Biopharmaceuticals, Ltd.
Sponsor Trial Information
Trial Location(s) and Contact(s) |
A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer
Number: NCT03574571
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 3
Sponsor(s): Memorial Sloan Kettering Cancer Center|Bayer
Sponsor Trial Information
Trial Location(s) and Contact(s) |
A Phase 1 Study of FOR46 in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Number: NCT03575819
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Fortis Therapeutics, Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Study of HPN424 in Patients With Advanced Prostate Cancer
Number: NCT03577028
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Harpoon Therapeutics
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Prostate Cancer Monitoring Using [18F]DCFPyL and Blood Based Biomarkers
Number: NCT03585114
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Emerson Lim|Columbia University
Sponsor Trial Information
Trial Location(s) and Contact(s) |
This Study is to Evaluate OBI-3424 Safe and Effective Treatment Dose in Subjects With Hepatocellular Carcinoma or Castrate Resistant Prostate Cancer
Number: NCT03592264
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): OBI Pharma, Inc
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Assessment of Multi-Modality Quantitative Imaging for Evaluation of Response of Metastatic Prostate Cancer to Therapy
Number: NCT03619655
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s) |
PRE-ProstAtectomy MRI-GuidEd Stereotactic Body RadioTherapy for High-Risk Prostate Cancer Trial (PREPARE SBRT)
Number: NCT03663218
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Weill Medical College of Cornell University
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Study of Drug 1 (Enzalutamide) Plus Drug 2 (Relacorilant) for Patients With Prostate Cancer
Number: NCT03674814
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): University of Chicago|Corcept Therapeutics|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s) |
A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer
Number: NCT03706365
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2|Phase 3
Sponsor(s): Eli Lilly and Company
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Study to Evaluate the Safety, Tolerability,Pharmacokinetics, and Antitumor Activity of a Thorium-227 Labeled Antibody-chelator Conjugate Alone and in Combination With Darolutamide, in Patients With Metastatic Castration Resistant Prostate Cancer
Number: NCT03724747
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Bayer
Sponsor Trial Information
Trial Location(s) and Contact(s) |
IMMU-132 in Patients With Metastatic Castration-Resistant Prostate Cancer Progressing on Second Generation AR-Directed Therapy
Number: NCT03725761
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): University of Wisconsin, Madison|National Cancer Institute (NCI)|Gilead Sciences
Sponsor Trial Information
Trial Location(s) and Contact(s) |
MGC018 With or Without MGA012 in Advanced Solid Tumors
Number: NCT03729596
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): MacroGenics
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Fractionated Docetaxel and Radium 223 in Metastatic Castration-Resistant Prostate Cancer
Number: NCT03737370
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Tufts Medical Center|Bayer|Lahey Clinic|Henry Ford Hospital|Ohio State University Comprehensive Cancer Center
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Enzalutamide With Venetoclax in Treating Patients With Metastatic Castration Resistant Prostate Cancer
Number: NCT03751436
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Roswell Park Cancer Institute|AbbVie
Sponsor Trial Information
Trial Location(s) and Contact(s) |
MGD019 DART® Protein in Unresectable/Metastatic Cancer
Number: NCT03761017
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): MacroGenics
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or Lymphoma
Number: NCT03775525
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Genzada Pharmaceuticals USA, Inc.|Translational Drug Development
Sponsor Trial Information
Trial Location(s) and Contact(s) |
SOR-C13 in Treating Patients With Advanced Refractory Solid Tumors
Number: NCT03784677
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): M.D. Anderson Cancer Center|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 160 in Subjects with MCRPC
Number: NCT03792841
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Amgen
Sponsor Trial Information
Trial Location(s) and Contact(s) |
A Study of ASP1951 in Subjects With Advanced Solid Tumors
Number: NCT03799003
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Astellas Pharma Global Development, Inc.|Merck Sharp & Dohme Corp.|Astellas Pharma Inc
Sponsor Trial Information
Trial Location(s) and Contact(s) |
177Lu-PSMA-617 and Pembrolizumab in Treating Patients With Metastatic Castration-Resistant Prostate Cancer
Number: NCT03805594
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): University of California, San Francisco|Prostate Cancer Foundation|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s) |
A Trial of CTT1403 for Metastatic Castration Resistant Prostate Cancer
Number: NCT03822871
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Cancer Targeted Technology|University of California, San Francisco
Sponsor Trial Information
Trial Location(s) and Contact(s) |
18F-DCFPyL Positron Emission Tomography (PET)/Computed Tomography (CT) in Men With Prostate Cancer
Number: NCT03824275
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2|Phase 3
Sponsor(s): Columbia University
Sponsor Trial Information
Trial Location(s) and Contact(s) |
WALNUTS for POWER: Polyphenols, Omega-3 Fatty Acids, Weight Loss, and EneRgy
Number: NCT03824652
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Stephen Freedland|California Walnut Commission|Cedars-Sinai Medical Center
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Effect of Perioperative Intravenous Lidocaine Infusion in Robotic-Assisted Urologic Surgery
Number: NCT03824808
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 4
Sponsor(s): University of Missouri-Columbia
Sponsor Trial Information
Trial Location(s) and Contact(s) |
TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers
Number: NCT03829436
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Tempest Therapeutics
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)
Number: NCT03834493
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 3
Sponsor(s): Merck Sharp & Dohme Corp.
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Platform Study for Prostate Researching Translational Endpoints Correlated to Response to Inform Use of Novel Combinations
Number: NCT03835533
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Parker Institute for Cancer Immunotherapy|Bristol-Myers Squibb|Celldex Therapeutics|Cancer Research Institute, New York City|Inovio Pharmaceuticals|Oncovir, Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s) |
A Parallel Arm Phase 1b/2a Study of DKN-01 as Monotherapy or in Combination With Docetaxel for the Treatment of Advanced Prostate Cancer With Elevated DKK1
Number: NCT03837353
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): NYU Langone Health|Leap Therapeutics, Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s) |
A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors
Number: NCT03845166
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Exelixis
Sponsor Trial Information
Trial Location(s) and Contact(s) |
A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors
Number: NCT03849469
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Xencor, Inc.|ICON Clinical Research
Sponsor Trial Information
Trial Location(s) and Contact(s) |
HC-1119 Versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Number: NCT03850795
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 3
Sponsor(s): Hinova Pharmaceuticals USA, Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Number: NCT03866382
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s) |
PSCA-CAR T Cells in Treating Patients With PSCA+ Metastatic Castration Resistant Prostate Cancer
Number: NCT03873805
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): City of Hope Medical Center|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
Number: NCT03878524
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): OHSU Knight Cancer Institute|Oregon Health and Science University
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Trial of ARV-110 in Patients With Metastatic Castration Resistant Prostate Cancer
Number: NCT03888612
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Arvinas Androgen Receptor, Inc.|Arvinas Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s) |
the Safety and Tolerability of Proxalutamide (GT0918) in Subjects With Metastatic Castrate Resistant Prostate Cancer
Number: NCT03899467
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Suzhou Kintor Pharmaceutical Inc,
Sponsor Trial Information
Trial Location(s) and Contact(s) |
CASCARA: Castration Sensitive Carboplatin, Cabazitaxel and Abiraterone
Number: NCT03934840
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Masonic Cancer Center, University of Minnesota
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Study of I-131-1095 Radiotherapy in Combination With Enzalutamide in Patients With Metastatic Castration-resistant Prostate Cancer Who Are Chemotherapy Naive and Have Progressed on Abiraterone
Number: NCT03939689
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Progenics Pharmaceuticals, Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s) |
A Pilot Study of 68-Ga PSMA 11 PET/MRI and 68-Ga RM2 PET/MRI for Evaluation of Prostate Cancer Response to HIFU or HDR Therapy
Number: NCT03949517
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Andrei Iagaru|General Electric|Stanford University
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Study of REGN5678 (Anti-PSMAxCD28) With Cemiplimab (Anti-PD-1) in Patients With Metastatic Castration-resistant Prostate Cancer
Number: NCT03972657
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Regeneron Pharmaceuticals
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Resistance Training +/- Creatine for Metastatic Prostate Cancer Patients
Number: NCT03987217
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Early Phase 1
Sponsor(s): University of Utah|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s) |
A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors
Number: NCT04032704
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Seagen Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Carboplatin or Olaparib for BRcA Deficient Prostate Cancer
Number: NCT04038502
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): VA Office of Research and Development
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib Patients With m-CRPC
Number: NCT04060394
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Laekna Limited
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Pharmacogenomics Testing in Directing the Optimal Use of Supportive Care Medications in Patients With Stage III-IV Cancer
Number: NCT04067960
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Early Phase 1
Sponsor(s): Mayo Clinic|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Study of NGM120 in Subjects With Advanced Solid Tumors and Pancreatic Cancer Using Combination Therapy
Number: NCT04068896
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): NGM Biopharmaceuticals, Inc
Sponsor Trial Information
Trial Location(s) and Contact(s) |
First-in-human Study of CCW702 in Patients With Metastatic Castration Resistant Prostate Cancer
Number: NCT04077021
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Calibr, a division of Scripps Research
Sponsor Trial Information
Trial Location(s) and Contact(s) |
pTVG-HP DNA Vaccine With or Without pTVG-AR DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate Cancer
Number: NCT04090528
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): University of Wisconsin, Madison|Merck Sharp & Dohme Corp.|Madison Vaccines, Inc|Prostate Cancer Foundation
Sponsor Trial Information
Trial Location(s) and Contact(s) |
A Study of Nivolumab or Placebo in Combination With Docetaxel in Men With Advanced Castration-resistant Prostate Cancer
Number: NCT04100018
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 3
Sponsor(s): Bristol-Myers Squibb
Sponsor Trial Information
Trial Location(s) and Contact(s) |
A Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas
Number: NCT04104776
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Constellation Pharmaceuticals
Sponsor Trial Information
Trial Location(s) and Contact(s) |
A Study of CHeckpoint Inhibitors in Men With prOgressive Metastatic Castrate Resistant Prostate Cancer Characterized by a Mismatch Repair Deficiency or Biallelic CDK12 Inactivation
Number: NCT04104893
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): VA Office of Research and Development|Merck Sharp & Dohme Corp.
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Study of Nivolumab in Combination w Radium-223 in Men w Metastatic Castration Resistant Prostate Cancer
Number: NCT04109729
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): University of Utah
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Safety and Targeting of Anti-hk2 Antibody in mCRPC
Number: NCT04116164
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Early Phase 1
Sponsor(s): Tomopath Inc.|Invicro|Janssen Research & Development, LLC
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Fecal Microbiota Transplant and Pembrolizumab for Men With Metastatic Castration Resistant Prostate Cancer.
Number: NCT04116775
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Julie Graff, MD|Merck Sharp & Dohme Corp.|Prostate Cancer Foundation|Johns Hopkins University|Oregon Health and Science University|Portland VA Medical Center
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC
Number: NCT04140526
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): OncoC4, Inc.|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Study to Compare the Effects of Drug Darolutamide and Drug Enzalutamide on Physical Function, Including Balance and Daily Activity, in Patients With Castration-resistant Prostate Cancer (CRPC)
Number: NCT04157088
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Bayer
Sponsor Trial Information
Trial Location(s) and Contact(s) |
18F-fluciclovine PET in Metastatic Castration Resistant Prostate Cancer Treated With Life Prolonging Therapies
Number: NCT04158245
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Tulane University|Blue Earth Diagnostics
Sponsor Trial Information
Trial Location(s) and Contact(s) |
ESK981 and Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer
Number: NCT04159896
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Barbara Ann Karmanos Cancer Institute|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s) |
CELLO-1, Study of Tazemetostat With Enzalutamide or Abiraterone/Prednisone in Subjects With Castration Resistant Prostate Cancer Who Have Not Received Chemotherapy
Number: NCT04179864
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Epizyme, Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Study of NMS-03305293 in Pts With Selected Advanced/Metastatic Solid Tumors
Number: NCT04182516
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Nerviano Medical Sciences
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Addition of Opaganib to Androgen Antagonists in Patients With mCRPC
Number: NCT04207255
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Medical University of South Carolina|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s) |
PRAGMA (Prostate Radio Ablation Guided by Magnetic Resonance Imaging Acquisition) in Metastatic Prostate Cancer
Number: NCT04220983
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Weill Medical College of Cornell University
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Study of AMG 509 in Subjects With Metastatic Castration-Resistant Prostate Cancer
Number: NCT04221542
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Amgen
Sponsor Trial Information
Trial Location(s) and Contact(s) |
TAEK-VAC-HerBy Vaccine for Brachyury and HER2 Expressing Cancer
Number: NCT04246671
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Bavarian Nordic
Sponsor Trial Information
Trial Location(s) and Contact(s) |
P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC)
Number: NCT04249947
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Poseida Therapeutics, Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s) |
A Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer
Number: NCT04253262
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Brown University|Rhode Island Hospital|The Miriam Hospital|Bayer|Clovis Oncology, Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Effect of Androgen Receptor Signaling Inhibitors on 68Ga-PSMA-11 PET/CT Imaging in Patients With Castration-Resistant Prostate Cancer
Number: NCT04279561
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Jonsson Comprehensive Cancer Center
Sponsor Trial Information
Trial Location(s) and Contact(s) |
PK and Dose Escalation and Expansion Study of DST-2970
Number: NCT04291664
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): DisperSol Technologies, LLC|Translational Drug Development
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Androgen Receptor Directed Therapy on Cognitive Function in Patients Treated With Darolutamide or Enzalutamide
Number: NCT04335682
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Alliance Foundation Trials, LLC.|Bayer
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Fatty Acid Synthase Inhibition in Castration Refractory Prostate Cancer
Number: NCT04337580
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Wake Forest University Health Sciences|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Biomarker Monitoring of Prostate Cancer Patients With RSI MRI (ProsRSI)
Number: NCT04349501
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): University of California, San Diego
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Sequential Testosterone and Enzalutamide Prevents Unfavorable Progression
Number: NCT04363164
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|United States Department of Defense
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer
Number: NCT04381832
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Arcus Biosciences, Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s) |
PRO-MERIT (Prostate Cancer Messenger RNA Immunotherapy)
Number: NCT04382898
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): BioNTech SE
Sponsor Trial Information
Trial Location(s) and Contact(s) |
DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers
Number: NCT04388852
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): M.D. Anderson Cancer Center|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s) |
A Study of JNJ-70218902 in Participants With Advanced Stage Solid Tumors
Number: NCT04397276
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Janssen Research & Development, LLC
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Oral EPI-7386 in Patients With Metastatic Castration-Resistant Prostate Cancer
Number: NCT04421222
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): ESSA Pharmaceuticals
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Study to Evaluate the Safety and Tolerability of CC-94676 in Participants With Metastatic Castration-Resistant Prostate Cancer
Number: NCT04428788
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Celgene
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC
Number: NCT04446117
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 3
Sponsor(s): Exelixis|Roche-Genentech|Takeda
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Prospective Exploratory Study of FAPi PET/CT in Prostate Cancer With Histopathology Validation
Number: NCT04457232
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Jonsson Comprehensive Cancer Center|Prostate Cancer Foundation
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Impact of Acetazolamide in Reducing Referred Postoperative Pain
Number: NCT04470843
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Medical College of Wisconsin
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Study in Patients With Advanced Cancers Associated With Expression of DLL3 Who Have Failed Standard Available Therapy
Number: NCT04471727
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Harpoon Therapeutics
Sponsor Trial Information
Trial Location(s) and Contact(s) |
ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Number: NCT04471974
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Rahul Aggarwal|Zenith Epigenetics|Merck Sharp & Dohme Corp.|U.S. Army Medical Research and Development Command|University of California, San Francisco
Sponsor Trial Information
Trial Location(s) and Contact(s) |
TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
Number: NCT04485013
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Tizona Therapeutics, Inc
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Hypofractionated Accelerated Pelvic Nodal Radiotherapy (GCC 2048)
Number: NCT04486755
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): University of Maryland, Baltimore
Sponsor Trial Information
Trial Location(s) and Contact(s) |
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic
Number: NCT04497844
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 3
Sponsor(s): Janssen Research & Development, LLC
Sponsor Trial Information
Trial Location(s) and Contact(s) |
A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies
Number: NCT04503265
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): AtlasMedx, Incorporated
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Fractionated and Multiple Dose 225Ac-J591 for Progressive mCRPC
Number: NCT04506567
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Weill Medical College of Cornell University
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
Number: NCT04514484
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Number: NCT04521686
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Eli Lilly and Company|Loxo Oncology, Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s) |
[18F]FLOR (FC303) PET/CT Imaging in Patients With Prostate Cancer
Number: NCT04528199
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|FutureChem
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors
Number: NCT04541225
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Nuvation Bio Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s) |
PLX2853 in Combination With Abiraterone Acetate and Prednisone and in Combination With Olaparib in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Number: NCT04556617
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Plexxikon
Sponsor Trial Information
Trial Location(s) and Contact(s) |
A Study Investigating DNA-damage Response Agents in Molecularly Altered Advanced Cancer
Number: NCT04564027
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): AstraZeneca
Sponsor Trial Information
Trial Location(s) and Contact(s) |
A Study of FT-7051 in Men With MCRPC
Number: NCT04575766
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Forma Therapeutics, Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Re-treatment 225Ac-J591 for mCRPC
Number: NCT04576871
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Early Phase 1
Sponsor(s): Weill Medical College of Cornell University
Sponsor Trial Information
Trial Location(s) and Contact(s) |
INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors
Number: NCT04580485
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Incyte Corporation
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.
Number: NCT04586335
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Haihe Biopharma Co., Ltd.
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer
Number: NCT04592237
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): M.D. Anderson Cancer Center|Janssen Pharmaceutica
Sponsor Trial Information
Trial Location(s) and Contact(s) |
To Evaluate if Green Tea Can be Effective in Reducing the Progression of Prostate Cancer in Men on Close Monitoring
Number: NCT04597359
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): ECOG-ACRIN Cancer Research Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Study of PF-07248144 in Advanced or Metastatic Solid Tumors
Number: NCT04606446
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Pfizer
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Treatment of Cancer-Related Bone Pain by Using Bone-Targeted Radiation-Based Therapy (Sn-117m-DTPA) in Patients With Prostate Cancer That Has Spread to Bones
Number: NCT04616547
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s) |
A Study of CC-90011 and Comparators in Participants With Prostate Cancer
Number: NCT04628988
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Celgene
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC)
Number: NCT04631601
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Amgen
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Cabozantinib in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Number: NCT04631744
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Weill Medical College of Cornell University|Exelixis
Sponsor Trial Information
Trial Location(s) and Contact(s) |
M9241 in Combination With Docetaxel in Adults With Metastatic Castration Sensitive and Castration Resistant Prostate Cancer
Number: NCT04633252
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Assess the Safety, Tolerability, PK and Anti-tumor Efficacy of DZD2269 in Patients With MCRPC
Number: NCT04634344
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Dizal Pharmaceuticals
Sponsor Trial Information
Trial Location(s) and Contact(s) |
A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer
Number: NCT04644770
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Janssen Research & Development, LLC
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment
Number: NCT04647526
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 3
Sponsor(s): POINT Biopharma
Sponsor Trial Information
Trial Location(s) and Contact(s) |
CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors
Number: NCT04660929
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Carisma Therapeutics Inc
Sponsor Trial Information
Trial Location(s) and Contact(s) |
ARX517 in Subjects With Advanced Solid Tumor
Number: NCT04662580
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Ambrx, Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer
Number: NCT04666129
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Myovant Sciences GmbH
Sponsor Trial Information
Trial Location(s) and Contact(s) |
177Lu-PSMA-617 vs. Androgen Receptor-directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer
Number: NCT04689828
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 3
Sponsor(s): Novartis Pharmaceuticals|Novartis
Sponsor Trial Information
Trial Location(s) and Contact(s) |
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resist
Number: NCT04691804
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 3
Sponsor(s): Jiangsu HengRui Medicine Co., Ltd.
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Utility of Hyperpolarized 13C-pyruvate Metabolic Magnetic Resonance Imaging
Number: NCT04698564
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): University of Maryland, Baltimore
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer
Number: NCT04703920
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): University of Michigan Rogel Cancer Center|Pfizer|Acrotech Biopharma LLC
Sponsor Trial Information
Trial Location(s) and Contact(s) |
A Study of Chemoimmunotherapy for the Treatment of Men With Neuroendocrine or Aggressive Variant Metastatic Prostate Cancer
Number: NCT04709276
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Andrew J. Armstrong, MD|Bristol-Myers Squibb|Duke University
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Proton Radiation Therapy for the Treatment of Patients With High Risk Prostate Cancer
Number: NCT04725903
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Not Applicable
Sponsor(s): Emory University|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors
Number: NCT04726332
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Exelixis
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Open-label, Multicenter Study of Intramuscular PRL-02 Depot in Patients With Advanced Prostate Cancer
Number: NCT04729114
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Propella Therapeutics
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Neoadjuvant Androgen Deprivation, Darolutamide, and Ipatasertib in Men With Localized, High Risk Prostate Cancer
Number: NCT04737109
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): David VanderWeele|Big Ten Cancer Research Consortium
Sponsor Trial Information
Trial Location(s) and Contact(s) |
A Study of TNB-585 in Subjects With Metastatic Castrate-Resistant Prostate Carcinoma
Number: NCT04740034
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Amgen
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Flibanserin in Men Receiving Androgen Suppression for Prostate Cancer
Number: NCT04743934
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Andrew McDonald|University of Alabama at Birmingham
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Abemaciclib With or Without Atezolizumab for mCRPC
Number: NCT04751929
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Dana-Farber Cancer Institute|Eli Lilly and Company|Genentech, Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Enfortumab Vedotin as Monotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer
Number: NCT04754191
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): University of Utah|Astellas Pharma Inc
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Erdafitinib for the Treatment of Patients With Castration-Resistant Prostate Cancer
Number: NCT04754425
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): M.D. Anderson Cancer Center
Sponsor Trial Information
Trial Location(s) and Contact(s) |
The Safety and Pharmacokinetics Preliminary Efficacy of IMP7068 in Patients With Advanced Solid Tumors
Number: NCT04768868
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Impact Therapeutics, Inc.|Covance
Sponsor Trial Information
Trial Location(s) and Contact(s) |
An Investigational Scan (68Ga-PSMA-11 PET/CT) for the Imaging of Prostate Cancer
Number: NCT04777071
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): University of Washington
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Neratinib in Patients With Metastatic Castration-Resistant Prostate Cancer
Number: NCT04781374
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Dana-Farber Cancer Institute|Puma Biotechnology, Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC
Number: NCT04821622
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 3
Sponsor(s): Pfizer|Astellas Pharma Inc
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Phase II Study of Pencil Beam Scanning Proton Stereotactic Body Radiation Therapy for Prostate Cancer
Number: NCT04842890
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): The New York Proton Center
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting Agent
Number: NCT04844749
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 3
Sponsor(s): Veru Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Phase Ia/Ib Talazoparib + Tazemetostat for mCRPC
Number: NCT04846478
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Dana-Farber Cancer Institute|Epizyme, Inc.|Pfizer
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Pembrolizumab and Lenvatinib in Advanced/Metastatic Neuroendocrine Prostate Cancer
Number: NCT04848337
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Ulka Vaishampayan|Merck Sharp & Dohme Corp.|University of Michigan|Hoosier Cancer Research Network
Sponsor Trial Information
Trial Location(s) and Contact(s) |
99mTc-PSMA-I&S Biodistribution in Patients With Prostate Cancer
Number: NCT04857502
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Early Phase 1
Sponsor(s): Jonsson Comprehensive Cancer Center
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Digital PET/CT Using [Ga-68]PSMA for Characterization of Prostate Lesions
Number: NCT04867603
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 3
Sponsor(s): Norbert Avril, M.D.|Case Comprehensive Cancer Center
Sponsor Trial Information
Trial Location(s) and Contact(s) |
64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE)
Number: NCT04868604
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Clarity Pharmaceuticals Ltd
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Phase II Study to Evaluate the Safety and Efficacy of Prostatic Artery Embolization
Number: NCT04879940
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): H. Lee Moffitt Cancer Center and Research Institute
Sponsor Trial Information
Trial Location(s) and Contact(s) |
225Ac-J591 Plus 177Lu-PSMA-I&T for mCRPC
Number: NCT04886986
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Weill Medical College of Cornell University|POINT Biopharma
Sponsor Trial Information
Trial Location(s) and Contact(s) |
TAVT-45 (Abiraterone Acetate) Granules in Patients With Prostate Cancer
Number: NCT04887506
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 3
Sponsor(s): Tavanta Therapeutics
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation
Number: NCT04890613
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Senhwa Biosciences, Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s) |
A Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate Cancer
Number: NCT04898634
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Janssen Research & Development, LLC
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Apalutamide Plus Cetrelimab in Patients With Treatment-Emergent Small Cell Neuroendocrine Prostate Cancer
Number: NCT04926181
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Rahul Aggarwal|Janssen Scientific Affairs, LLC|University of California, San Francisco
Sponsor Trial Information
Trial Location(s) and Contact(s) |
11C-YJH08 PET Imaging for the Detection of Glucocorticoid Receptor Expression in Patients With Metastatic Prostate Cancer
Number: NCT04927663
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Michael Evans|U.S. Army Medical Research Acquisition Activity|National Institute of Mental Health (NIMH)|University of California, San Francisco
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Dose Escalation and Dose Expansion Study of CPO-100 in Patients With Advanced Solid Tumors
Number: NCT04931823
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Conjupro Biotherapeutics, Inc.|CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Maximizing Responses to Anti-PD1 Immunotherapy With PSMA-targeted Alpha Therapy in mCRPC
Number: NCT04946370
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Weill Medical College of Cornell University|United States Department of Defense|Merck Sharp & Dohme Corp.
Sponsor Trial Information
Trial Location(s) and Contact(s) |
A Study of NOX66 and External Beam Radiotherapy in Patients With Metastatic Castration-resistant Prostate Cancer and Other Solid Tumors
Number: NCT04957290
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Noxopharm Limited
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Pharmacokinetics of IA and IV Ga68-PSMA-11 Infusion
Number: NCT04976257
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Early Phase 1
Sponsor(s): Ryan Kohlbrenner, MD|Radiological Society of North America|University of California, San Francisco
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Randomized Trial of Five or Two MRI-Guided Adaptive Radiotherapy Treatments for Prostate Cancer
Number: NCT04984343
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Weill Medical College of Cornell University|Viewray Inc.|Progenics Pharmaceuticals, Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s) |
ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer
Number: NCT04986423
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Zenith Epigenetics|Astellas Pharma Inc|Newsoara Biopharma Co., Ltd.
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Prostate Cancer Registry of Outcomes and Germline Mutations (PROMISE)
Number: NCT04995198
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Not Applicable
Sponsor(s): Prostate Cancer Clinical Trials Consortium|Memorial Sloan Kettering Cancer Center|Fred Hutchinson Cancer Research Center|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Advancing Cancer Treatment, Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s) |
XmAb®20717 Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer
Number: NCT05005728
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Xencor, Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s) |
The Safety and Tolerability of PGV001-based Personalized Multi-peptide Vaccines in the Adjuvant Setting.
Number: NCT05010200
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Ashutosh Kumar Tewari|Icahn School of Medicine at Mount Sinai
Sponsor Trial Information
Trial Location(s) and Contact(s) |
FOR46 in Combination With Enzalutamide in Patients With Metastatic Castration Resistant Prostate Cancer
Number: NCT05011188
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Rahul Aggarwal|Fortis Therapeutics, Inc.|University of California, San Francisco
Sponsor Trial Information
Trial Location(s) and Contact(s) |
A Study of JNJ-75229414 for Metastatic Castration-resistant Prostate Cancer Participants
Number: NCT05022849
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Janssen Research & Development, LLC
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Decitabine/Cedazuridine and Enzalutamide for the Treatment of Metastatic Castrate Resistant Prostate Cancer
Number: NCT05037500
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Roswell Park Cancer Institute|National Comprehensive Cancer Network
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Differences in Immunological Effects of Vitamin D Replacement Among African American Prostate Cancer Patients With Localized Versus Metastatic Disease
Number: NCT05045066
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Early Phase 1
Sponsor(s): Mayo Clinic|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s) |
KZR-261 in Subjects With Advanced Solid Malignancies
Number: NCT05047536
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Kezar Life Sciences, Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score
Number: NCT05050084
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 3
Sponsor(s): NRG Oncology|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer
Number: NCT05053152
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): NRG Oncology|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Modifying Metabolic Syndrome and Cardiovascular Risk for Prostate Cancer Patients on ADT Using a Risk Factor Modification Program and Continuous Fitbit Monitoring
Number: NCT05054296
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): M.D. Anderson Cancer Center|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Clinical Trial to Evaluate ARV-766 in Patients With Metastatic Castration-Resistant Prostate Cancer
Number: NCT05067140
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Arvinas Androgen Receptor, Inc.|Arvinas Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s) |
EPI-7386 in Combination With Enzalutamide Compared With Enzalutamide Alone in Subjects With mCRPC
Number: NCT05075577
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): ESSA Pharmaceuticals
Sponsor Trial Information
Trial Location(s) and Contact(s) |
A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Orally Administered SM08502 Combined With Hormonal Therapy or Chemotherapy in Subjects With Advanced Solid Tumors
Number: NCT05084859
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Biosplice Therapeutics, Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s) |
REGN4336 (a PSMAXCD3 Bispecific Antibody) Administered Alone or in Combination With Cemiplimab in Adult Male Patients With Metastatic Castration-Resistant Prostate Cancer
Number: NCT05125016
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Regeneron Pharmaceuticals
Sponsor Trial Information
Trial Location(s) and Contact(s) |
A Study of PRT2527 in Patients With Advanced Solid Tumors
Number: NCT05159518
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Prelude Therapeutics
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Image-Guided (68Ga-PSMA-11 PET/CT) Prostate Biopsy for the Diagnosis of Prostate Cancer in Men With Prior Negative/Inconclusive Biopsy
Number: NCT05160597
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Early Phase 1
Sponsor(s): Jonsson Comprehensive Cancer Center
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial
Number: NCT05168618
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): University of Utah|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s) |
A Study of BMS-986218 or BMS-986218 Plus Nivolumab in Combination With Docetaxel in Participants With Metastatic Castration-resistant Prostate Cancer
Number: NCT05169684
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Bristol-Myers Squibb
Sponsor Trial Information
Trial Location(s) and Contact(s) |
A Study of Stereotactic Body Radiation Therapy (SBRT) Without Androgen Deprivation Therapy (ADT) in People With Unfavorable Intermediate-Risk Prostate Cancer
Number: NCT05169970
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Memorial Sloan Kettering Cancer Center
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Study of XL092 in Combination With Immuno-Oncology Agents in Subjects With Solid Tumors
Number: NCT05176483
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Exelixis
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Trial of ARV-110 and Abiraterone in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
Number: NCT05177042
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Arvinas Androgen Receptor, Inc.|Arvinas Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Study of SRF617 With AB928 (Etrumadenent) and AB122 (Zimberelimab) in Patients With Metastatic Castration Resistant Prostate Cancer
Number: NCT05177770
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Surface Oncology|Arcus Biosciences, Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Lu-177-PSMA-I&T for Metastatic Castration-Resistant Prostate Cancer
Number: NCT05204927
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 3
Sponsor(s): Curium US LLC
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Study of NGM831 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors
Number: NCT05215574
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): NGM Biopharmaceuticals, Inc
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Targeted Alpha Therapy With 225Actinium-PSMA-I&T of Castration-resISTant Prostate Cancer (TATCIST).
Number: NCT05219500
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Excel Diagnostics and Nuclear Oncology Center
Sponsor Trial Information
Trial Location(s) and Contact(s) |
PET Imaging Study of 89Zr-DFO-YS5
Number: NCT05245006
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Robert Flavell, MD, PhD|United States Department of Defense|Fortis Therapeutics, Inc.|University of California, San Francisco
Sponsor Trial Information
Trial Location(s) and Contact(s) |
64Cu-SAR-bisPSMA for Identification of Participants With Recurrence of Prostate Cancer (COBRA)
Number: NCT05249127
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Clarity Pharmaceuticals Ltd
Sponsor Trial Information
Trial Location(s) and Contact(s) |
NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors
Number: NCT05252390
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Nuvation Bio Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s) |
A Study of Orally Administered JBI-802, an LSD1/HDAC6 Inhibitor, in Patients With Advanced Solid Tumors
Number: NCT05268666
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Jubilant Therapeutics Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s) |
A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors
Number: NCT05293496
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): MacroGenics
Sponsor Trial Information
Trial Location(s) and Contact(s) |
A Study of EPI-7386 in Combination With Abiraterone Acetate Plus Prednisone, or Apalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC)
Number: NCT05295927
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Janssen Research & Development, LLC
Sponsor Trial Information
Trial Location(s) and Contact(s) |
